Home › Merck Provides Update on Next Steps for TREDAPTIVE (extended-release niacin/laropiprant)
 

Keywords :   


Merck Provides Update on Next Steps for TREDAPTIVE (extended-release niacin/laropiprant)

2013-01-11 13:39:00| Merck.com - Research & Development News

Dateline City:  WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the company is taking steps to suspend the availability of TREDAPTIVE (extended-release niacin/laropiprant) tablets worldwide. TREDAPTIVE is not approved for use in the United States. Language:  English Contact HTML:  MerckMedia:Pamela Eisele, 908-423-5042orSkip Irvine, 267-305-5397orInvestors:Carol Ferguson, 908-423-4465orJustin Holko, 908-423-5088 Ticker Slug:  Ticker: MRK Exchange: NYSE read more

Tags: update steps merck extendedrelease

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
30.09Post Office minister 'horrified' at more IT faults
30.09PPGs SEM Products Business Launches Performance Abrasives Product Line
30.09Pulse demonstrates Monolox at Mark Andy Poland workshop
30.09EMT International names John Pecoraro regional sales manager
30.09IDENTCO chosen by watercraft provider for label durability
30.09New Product Line: MIPA Combines Quality with Sustainability
30.09HiFlow Solutions appoints Alfonso Hernandez, Jr. VP of sales
30.09Tropical Storm Kirk Graphics
More »